ERBB2 and gastric cancer: HER2 was the first recognised treatment target in GEA, based on the results of adding trastuzumab to platinum-based chemotherapy in the Trastuzumab for Gastric Cancer (ToGA) trial for the treatment of HER2-positive advanced disease [7].